Mai 19th, 2012 by blandos
|
Vorhofflimmern: Nieren-Kontrolle ist Pflicht
Ärzte Zeitung Die beiden derzeit in Deutschland zugelassenen neuen oralen Antikoagulanzien sind der Thrombinhemmer Dabigatran und der Faktor Xa-Hemmer Rivaroxaban. Zu erwarten sei außerdem die baldige Markteinführung von Apixaban, das ebenfalls am Faktor Xa ansetzt. |
Mai 18th, 2012 by blandos
|
Pradaxa – A Misfire?
InjuryBoard.com The problem with dabigatran is that it has been presented as a "fire-and-forget" medicine. That is, the doctor can write a prescription and not think about it again. But anticoagulation is not like that. Just because patients on dabigatran don't need … |
Mai 18th, 2012 by blandos
|
Biosensors' BioMatrix Flex chosen for largest clinical trial involving drug …
pharmabiz.com Ticagrelor is a new anti-platelet drug. Recruitment is due to commence by the end of this year. Patients will be followed-up for two years. “BioMatrix Flex is a logical choice as the stent platform for Global Leaders”, commented Prof. Serruys. |
Mai 16th, 2012 by blandos
|
New Study Shows Anticoagulant Medication Not as Safe in Real World
Law Firm Newswire (press release) Houston, TX (Law Firm Newswire) May 16, 2012 – Preliminary results from a large study comparing the new anticoagulant medication dabigatran (Pradaxa®) to warfarin (Coumadin®), a drug widely used since 1954, confirms safety concerns. |
Mai 16th, 2012 by blandos
 Deutsches Ärzteblatt |
Pharmafirmen wollen Rolle als Gestalter einnehmen
Deutsches Ärzteblatt Die Verhandlungen zu dem Medikament Brillique mit dem Wirkstoff Ticagrelor, dem ersten Arzneimittel, dem vom Gemeinsamen Bundesausschuss ein Zusatznutzen bescheinigt worden war, haben auch nach vier Verhandlungsterminen zu keinem Ergebnis geführt. |
Mai 14th, 2012 by blandos
|
Pradaxa More Dangerous than Warfarin
CisionWire (press release) Dr. Mark Wurster and his colleagues analyzed the clinical records of 113 patients who had switched their treatment plan from warfarin to dabigatran – the active drug in Pradaxa. Patients who were analyzed took the drug for a mean time of nearly four … |
Mai 14th, 2012 by blandos
|
HRS: To have or to hold—anticoagulation use during device procedure
Cardiovascular Business Giudici also touched on heparin use during AF ablation in patients who received dabigatran (Pradaxa, Boehringer Ingelheim) and warfarin. “We use a heck of a lot more heparin in patients on Pradaxa compared with those on warfarin,” he said. |
Mai 13th, 2012 by blandos
 ModernMedicine |
New CAD/ACS antiplatelet agents a mixed bag
ModernMedicine Emerging agents for the treatment of CAD and ACS include the reversible P2Y12 antagonists ticagrelor (approved July 2011) and cangrelor. Development of elinogrel, another drug in this class, was stopped in January 2012. |
Mai 13th, 2012 by blandos
|
Mehr Bewegung, weniger Fett
Allgemeine Zeitung Mainz Alternativen zum Blutverdünner Marcumar (wie Dabigatran oder Rivaroxaban) präsentierte Prof. Dr. Helmut Schinzel, Spezialist des Thrombosezentrums. Verändert werde die Wirkungsweise, falls die Patienten zusätzlich Johanniskraut-Präparate einnähmen. |
Mai 11th, 2012 by blandos
|
New blood thinners offer new benefits, but also some drawbacks
Chicago Tribune The new anticoagulant drugs include dabigatran, approved by the FDA in 2010, and rivaroxaban, approved in 2011. The FDA is currently reviewing a third, called apixaban. In studies, these drugs appear to be safer than warfarin in terms of bleeding … |